Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

A Phase III, Multicentre, Randomised, Double Blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of a Single Administration of COMP360 in Participants With Treatment-resistant Depression

To see complete record on, please visit this link

Id: NCT05624268

Organisation Name: COMPASS Pathways

Overal Status: Recruiting

Start Date: January 19, 2023

Last Update: February 1, 2023

Lead Sponsor: COMPASS Pathways

Brief Summary: Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

  • Treatment Resistant Depression

Total execution time in seconds: 0.26556897163391